MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de David Geffen School of Medicine at UCLA](/img/noimage_org.png)
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublications in collaboration with researchers from David Geffen School of Medicine at UCLA (22)
2023
-
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 2
2022
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390
2021
-
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
Annals of Oncology
-
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024
2020
-
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72
-
Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer
Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy
JNCI Cancer Spectrum, Vol. 4, Núm. 1
-
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524
-
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180
2019
-
Assessment of ERBB2 / HER2 Status in HER2 -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
JAMA Oncology, Vol. 5, Núm. 3, pp. 366-375
-
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study
Journal of Clinical Oncology
2018
-
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680
-
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126
2016
-
HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials
Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528
-
Palbociclib and letrozole in advanced breast cancer
New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936
2015
-
PTEN loss is associated with worse outcome in HER2-Amplified breast cancer patients but is not associated with trastuzumab resistance
Clinical Cancer Research, Vol. 21, Núm. 9, pp. 2065-2074
2013
2011
-
Adjuvant trastuzumab in HER2-positive breast cancer.
The New England journal of medicine, Vol. 365, Núm. 14, pp. 1273-1283